Ventana Medical Systems, Inc., established the Molecular Discovery Systems (MDS) division to leverage the Company’s core business of immunohistochemistry and in situ hybridization slide processing technology in drug discovery and research laboratories. The Discovery^® Series (the Discovery and the Discovery XT system) systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug candidates. These systems are also ideal systems for hybridizing nucleic acid microarrays*, which can be used to identify differential gene expressions between diseased and normal tissue, confirm gene activity in tissue, identify proteins encoded by active genes, and evaluate the toxicity profile of new drug compounds.

MDS offers quality solutions for slide-based applications, including IHC, ISH, and microarrays*. We serve the non-clinical life science research market composed of pharmaceutical companies, biotechnology companies, and academic institutions. MDS offers a high-quality multivalent system solution that provides enhanced productivity, reliability and reproducibility for one or more applications. We are a leading provider of fully integrated systems with a proven system consisting of instrumentation, reagents, and software. Our highly technical and competent sales and support organization leverages our expertise in this market by providing unmatched service.

Ventana Medical Systems is committed to providing quality instrumentation and reagents to health care providers around the world, and MDS is dedicated to providing the premier automated advanced slide staining systems for the scientific research community.

Benefits of MDS

• Enable automation and optimization in a research environment
• Enhance productivity in drug discovery process and basic research
• Drive reproducibility, sensitivity, performance
• Support end-user applications